Thoracoscopic completion thymectomy in refractory nonthymomatous myasthenia

Ann Thorac Surg. 2000 Sep;70(3):918-23. doi: 10.1016/s0003-4975(00)01566-6.

Abstract

Background: The aim of this study was to assess the efficacy of thoracoscopic completion thymectomy in patients with refractory nonthymomatous myasthenia.

Methods: Eight patients were operated upon after transcervical (n = 6) or transsternal (n = 2) thymectomy. The mean interval between operations was 129 months. Every patient was completely disabled despite treatment with large dosages of prednisone in combination with pyridostigmine (n = 5) or azathioprine (n = 3) and with repeated plasma exchanges.

Results: Gross (n = 5) or microscopic (n = 3) residual thymic tissue was found in all patients. There was no mortality, but morbidity included 2 patients with postoperative myasthenic crisis requiring reintubation and mechanical ventilation. The mean hospital stay was 4.75 days. The mean follow-up was 28.3 months. At the last follow-up, 6 patients had achieved symptomatic improvement as expressed by significant change in mean Osserman class (3.37 versus 2.12, p = 0.03), and prednisone dosage (43 versus 20 mg/d, p = 0.03). Conversely, there was no difference in dosage of pyridostigmine and azathioprine or in number of exchange cycles.

Conclusions: Our results suggest that thoracoscopic completion thymectomy may be beneficial for selected patients with refractory nonthymomatous myasthenia.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Follow-Up Studies
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Myasthenia Gravis / surgery*
  • Postoperative Complications
  • Reoperation
  • Thoracoscopy*
  • Thymectomy / methods*
  • Time Factors
  • Treatment Outcome